Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels - PubMed (original) (raw)
Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels
J Kiehn et al. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar.
Abstract
The human ether-a-go-go-related gene (HERG) encodes a K+ channel with biophysical properties nearly identical to the rapid component of the cardiac-delayed rectifier K+ current (I(Kr)). HERG channels are one primary target for the pharmacological management of arrhythmias. In this study, we investigated the acute effects of the class III antiarrhythmic drug amiodarone on HERG channels expressed heterologously in Xenopus oocytes by use of the two-microelectrode voltage clamp technique. Amiodarone blocked HERG channels with an IC50 of 9.8 microM with a maximum outward tail current reduction of 62.8%. The block consisted of two main components, a closed channel block that could not be reversed within the time of experiments and an open channel block with a slow unblock, having a recovery time constant of 73 s at -80 mV. Inactivation of the HERG channel at very positive potentials could not prevent amiodarone block. These results indicate that HERG channels can be blocked by amiodarone in closed, open and inactivated states. The block of open channels was cumulative, use-dependent and voltage-dependent. In summary, our data suggest that the strong class III antiarrhythmic action of amiodarone is at least partially based upon its acute inhibitory effects on HERG potassium channels.
Similar articles
- High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
Thomas D, Wendt-Nordahl G, Röckl K, Ficker E, Brown AM, Kiehn J. Thomas D, et al. J Pharmacol Exp Ther. 2001 May;297(2):753-61. J Pharmacol Exp Ther. 2001. PMID: 11303067 - Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides.
Spector PS, Curran ME, Keating MT, Sanguinetti MC. Spector PS, et al. Circ Res. 1996 Mar;78(3):499-503. doi: 10.1161/01.res.78.3.499. Circ Res. 1996. PMID: 8593709 - Molecular determinants of dofetilide block of HERG K+ channels.
Ficker E, Jarolimek W, Kiehn J, Baumann A, Brown AM. Ficker E, et al. Circ Res. 1998 Feb 23;82(3):386-95. doi: 10.1161/01.res.82.3.386. Circ Res. 1998. PMID: 9486667 - HERG K+ channels: friend and foe.
Vandenberg JI, Walker BD, Campbell TJ. Vandenberg JI, et al. Trends Pharmacol Sci. 2001 May;22(5):240-6. doi: 10.1016/s0165-6147(00)01662-x. Trends Pharmacol Sci. 2001. PMID: 11339975 Review. - Biophysical properties and molecular basis of cardiac rapid and slow delayed rectifier potassium channels.
Mitcheson JS, Sanguinetti MC. Mitcheson JS, et al. Cell Physiol Biochem. 1999;9(4-5):201-16. doi: 10.1159/000016317. Cell Physiol Biochem. 1999. PMID: 10575198 Review.
Cited by
- Allocryptopine and benzyltetrahydropalmatine block hERG potassium channels expressed in HEK293 cells.
Lin K, Liu YQ, Xu B, Gao JL, Fu YC, Chen Y, Xue Q, Li Y. Lin K, et al. Acta Pharmacol Sin. 2013 Jun;34(6):847-58. doi: 10.1038/aps.2012.176. Epub 2013 Mar 25. Acta Pharmacol Sin. 2013. PMID: 23524574 Free PMC article. - Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.
Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA. Thomas D, et al. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. doi: 10.1007/s00210-004-0931-8. Epub 2004 Apr 20. Naunyn Schmiedebergs Arch Pharmacol. 2004. PMID: 15098086 - Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.
Zhang Y, Colenso CK, El Harchi A, Cheng H, Witchel HJ, Dempsey CE, Hancox JC. Zhang Y, et al. Biochem Pharmacol. 2016 Aug 1;113:24-35. doi: 10.1016/j.bcp.2016.05.013. Epub 2016 May 30. Biochem Pharmacol. 2016. PMID: 27256139 Free PMC article. - Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.
Obers S, Staudacher I, Ficker E, Dennis A, Koschny R, Erdal H, Bloehs R, Kisselbach J, Karle CA, Schweizer PA, Katus HA, Thomas D. Obers S, et al. Naunyn Schmiedebergs Arch Pharmacol. 2010 May;381(5):385-400. doi: 10.1007/s00210-010-0496-7. Epub 2010 Mar 13. Naunyn Schmiedebergs Arch Pharmacol. 2010. PMID: 20229012 - Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein.
Gierten J, Ficker E, Bloehs R, Schlömer K, Kathöfer S, Scholz E, Zitron E, Kiesecker C, Bauer A, Becker R, Katus HA, Karle CA, Thomas D. Gierten J, et al. Br J Pharmacol. 2008 Aug;154(8):1680-90. doi: 10.1038/bjp.2008.213. Epub 2008 Jun 2. Br J Pharmacol. 2008. PMID: 18516069 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources